Group
A study led by the University of Barcelona in collaboraiton with the Institute for Bioengineering of Catalonia reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether specific treatments will be effective in non-small cell lung cancer patients. The technique helps determine which therapy will be most effective by testing it directly on living cells, improving personalised therapies.
Científicos del Instituto de Bioingeniería de Cataluña (IBEC) y del CIBER-BBN han desarrollado un método que mejora la precisión de los sensores olfativos basados en receptores biológicos. Este avance permite … Read more
A study led by the Institute for Bioengineering of Catalonia (IBEC) and the CIBER’s Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) describes a method that mimics the physiological response to smell. The system makes it possible to discriminate between odours with very similar characteristics based on the binding interaction with the receptor, which causes a change in the capacitive response of the receptor. The application of this methodology opens the door to the development of highly selective olfactory biosensors.
The Institute for Bioengineering of Catalonia and the Sant Joan de Déu Barcelona Children’s Hospital have held a joint conference to strengthen collaboration in bioengineering and translational medicine. The event, held this morning at the IBEC, highlighted innovative projects, presented a joint PhD programme and encouraged the exchange of ideas between researchers from both institutions.
The latest developments in nanotechnology, biotechnology and medicine were presented at the NanoBio&Med 2024 International Conference, held this week at the Barcelona Science Park (PCB) from 5 to 7 November. This is an annual event designed to establish new collaborations and promote innovative projects in the scientific-industrial sector.
Two studies led by IBEC have successfully mimicked the transdifferentiation process of the neuroblastoma vasculature in in vitro models. These models, one in 2D and the other on a microfluidic chip, provide platforms for identifying new biomarkers and designing effective therapies against this type of cancer.
The project focuses on developing a chip that will serve as a model for testing new drugs to treat neuroblastoma, a childhood brain cancer. The research has received €200,000 in funding and is led by Aránzazu Villasante, Senior Researcher at IBEC.
Researchers from the IBEC and the University of Barcelona (UB) have identified new biomarkers for non-small cell lung cancer, the most common lung cancer. The results, published in the journal Modern … Read more
